The Medical Letter on Drugs and Therapeutics
Delayed-Release Prednisone (Rayos)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a delayed-release oral formulation of prednisone (Rayos – Horizon Pharma). Rayos is not labeled for any specific indication, but the only published studies of the new product have been in patients with rheumatoid arthritis (RA).

THE NEW FORMULATION — Rayos consists of a core prednisone tablet surrounded by an inactive shell. When taken with food, the inactive shell dissolves over 4 hours, delaying the absorption of the inner tablet. The plasma concentrations achieved with the delayedrelease tablet are comparable to those of standard prednisone, with a 4-hour delay.

RATIONALE — Serum concentrations of pro-inflammatory cytokines are highest at night, and RA symptoms such as joint pain and stiffness are often most severe in the morning. Taking a dose of prednisone that is absorbed in the middle of the night might be helpful in relieving these ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Delayed-Release Prednisone (Rayos)
Article code: 1404b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian